November 21, 2023
PCR London Valves Data Presentation: 30-Day Hemodynamic Results from the DurAVR® THV US EFS Trial
At the 2023 PCR London Valves conference, Dr Azeem Latib presented 30-day data from the US Early Feasibility Study (EFS) for the DurAVR® Transcatheter Heart Valve (THV). The preliminary results 30 days post-procedure included data from 12 out of the 15 enrolled patients (three patients awaiting scheduling).